For heart failure(HF) patients with reduced ejection fraction and atrial fibrillation (AF) with rapid ventricular response, cardiac resynchronization therapy (CRT) combined with atrioventricular junction ablation (AVJA) is an important treatment strategy. This article reports a case of HF with AF with rapid ventricular response in which the left ventricular lead implantation of CRT failed, and was successfully treated with left bundle branch pacing(LBBP) combined with AVJA and related literature is reviewed.

Objectives To compare the hemorrhage complications between the coadministration of dronedarone and rivaroxaban and that of amiodarone and rivaroxaban after radiofrequency ablation in patients with atrial fibrillation (AF). Methods Fifty patients with AF and abnormal thyroid function were administered dronedarone and rivaroxaban (Group D-R) after catheter ablation, and fifty patients with AF and normal thyroid function received dronedarone and rivaroxaban (Group A-R) after the operation were matched using propensity score matching. All patients returned for follow-up once a month for 3 months. The incidence of minor hemorrhage, massive hemorrhage, thromboembolism, and the recurrence rate of atrial fibrillation were observed. Results No significant difference was noted in the incidence of postoperative minor bleeding between the Group D-R and the Group A-R（2% versus 4%, P=0.558）, and no massive hemorrhage and ischemic events were detected in both groups. Also, no significant difference was observed in recurrence rate of AF between two groups(18% versus 16%, P=0.790). Conclusions Compared to the coadministration of amiodarone and rivaroxaban, that of dronedarone and rivaroxaban does not increase the risk of hemorrhage, thromboembolism and AF recurrence after radiofrequency ablation.